Patients who were told they had a 1-in-10 chance of winning $50 were more likely to complete home stool blood tests that help screen for colon cancer, according to a new study led by a researcher at the VA Ann Arbor Healthcare System and University of Michigan. The findings appear in a special issue of Annals of Internal Medicine…
Hundreds of mutations occur every day in almost every cell in our body. The protein p53 is then activated in order to limit these changes in the genome: either the cell repairs the damaged DNA or, if that is not possible, it triggers the cellular suicide program. In this way, cells are normally protected against the development of cancer. As the Berlin-based team at the Max Planck Institute for Infection Biology reported last year, chlamydial infections lead to a drastic increase in the mutation rate. …
But what happens to these drugs? When do they become accessible to cancer patients — if at all? In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice. “Bringing a new medication to clinical practice is a lengthy process and involves many stakeholders with a very diverse background, ranging from researchers, regulatory agencies, payers, physicians and patients,” says Dr Felipe Ades of the Jules Bordet Institute, lead author of the review…
Clinicians term an individual’s initial diagnosis a first primary cancer. A second primary cancer is one diagnosed at some point after the first diagnosis. …
A membrane channel is a family of proteins that allows the movement of ions, water or other solutions to pass through the membrane. These findings are being published in the Nov. 10, 2014, edition of the journal Cancer Cell. …
Led by Professor Jean Paul Thiery, Senior Principal Investigator, and Dr Ruby Huang, Principal Associate, both from CSI Singapore, the scientists developed a scoring scheme which monitors the epithelial-mesenchymal transition (EMT) mechanism. This process was shown to play a role in a large number of cancer-related events, including cancer invasion, metastasis, and chemo-resistance…
The new method relies upon a specifically sequenced type of small interfering RNA — or siRNA. …
Preclinical studies of oncolytic virus therapy in malignant glioma are promising; however, a potential problem with this approach is that the body’s own immune system can recognize the virus and clear the infection, resulting in reduced therapeutic effects. For this study, researchers used a mouse model with an intact immune system to mimic what would occur in humans to determine how the immune system clears the oncolytic virus. They found that the area surrounding malignant gliomas has a high number of immune cells called microglial cells and macrophages…
A group working out of Alberta Health Services’ Tom Baker Cancer Centre and the University of Calgary Department of Oncology has demonstrated that telomeres — protein complexes at the end of chromosomes — maintain their length in breast cancer survivors who practise meditation or are involved in support groups, while they shorten in a comparison group without any intervention. Although the disease-regulating properties of telomeres aren’t fully understood, shortened telomeres are associated with several disease states, as well as cell aging, while longer telomeres are thought to be protective against disease. …
If it hurts to pass water, or if there is blood in one’s urine, this could be a sign of bladder cancer. …